This Horizon Scan Bulletin provides information on advanced pipeline drugs intended to treat relapsed or refractory peripheral T-cell lymphoma (RR-PTCL). It describes the characteristics of completed phase II and III trials with published results evaluating drugs to treat RR-PTCL that are not currently approved by Health Canada or are under review.
Various formulations of buprenorphine, including extended-release depot injection and transmucosal tablet and film, are used to treat opioid use disorder. An Environmental Scan was performed to explore the provision of these formulations in correctional settings. A survey of 29 individuals representing Canadian correctional facilities or health authorities revealed that all offered the depot injection, but some lacked the transmucosal tablet or film. Eligibility for opioid agonist therapy typically requires a diagnosis, positive urine test, or prescription.
The monitoring of vital signs is a key component of patient care. Metrics such as heart rate, body temperature, respiratory rate, and oxygen saturation allow health care staff to monitor the well-being of their patients.
Shortage events, the phenomena when demand exceeds supply, can affect both medical care and medical devices. The COVID-19 pandemic caused a global shortage event, the consequences of which are still being experienced beyond the peak of the pandemic (e.g., the lack of pediatric pain medication available in fall 2022).
Children are vulnerable to shortage events as they represent a small proportion of the overall population, have distinct needs, and the pediatric medical device market has historically offered a lack of options.